N
BSX icon

Natixis’s Boston Scientific BSX Stock Holding History

Natixis’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-63,900
Closed -$2.96M – 1004
2022
Q4 		$2.96M Buy
+63,900
New +$2.77M 0.02% 472

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Natixis's BSX Position: Q1 2026 in Review

Natixis reduced its Boston Scientific (BSX) stake by 2.5% in Q1 2026, selling an estimated $1.12M and leaving 540,063 shares worth $33.9M. The position accounts for 0.12% of the portfolio, ranked #118.

Natixis first reported a position in BSX in Q2 2013 and has held it in 45 quarters since. The position peaked at $74.7M in Q4 2021. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Natixis held 540,063 shares of Boston Scientific worth $33.9M as of Q1 2026.
  • Natixis sold 13,948 Boston Scientific shares in Q1 2026, an estimated $1.12M.
  • Boston Scientific made up 0.12% of Natixis's portfolio in Q1 2026, its #118 holding.
  • Natixis first reported a position in Boston Scientific in Q2 2013 and has held it in 45 quarters since.
  • Natixis's Boston Scientific position peaked at $74.7M in Q4 2021.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.